Association between drug insurance cost sharing strategies and outcomes in patients with chronic diseases: a systematic review

Bikaramjit S Mann, Lianne Barnieh, Karen Tang, David J T Campbell, Fiona Clement, Brenda Hemmelgarn, Marcello Tonelli, Diane Lorenzetti, Braden J Manns, Bikaramjit S Mann, Lianne Barnieh, Karen Tang, David J T Campbell, Fiona Clement, Brenda Hemmelgarn, Marcello Tonelli, Diane Lorenzetti, Braden J Manns

Abstract

Background: Prescription drugs are used in people with hypertension, diabetes, and cardiovascular disease to manage their illness. Patient cost sharing strategies such as copayments and deductibles are often employed to lower expenditures for prescription drug insurance plans, but the impact on health outcomes in these patients is unclear.

Objective: To determine the association between drug insurance and patient cost sharing strategies on medication adherence, clinical and economic outcomes in those with chronic diseases (defined herein as diabetes, hypertension, hypercholesterolemia, coronary artery disease, and cerebrovascular disease).

Methods: Studies were included if they examined various cost sharing strategies including copayments, coinsurance, fixed copayments, deductibles and maximum out-of-pocket expenditures. Value-based insurance design and reference based pricing studies were excluded. Two reviewers independently identified original intervention studies (randomized controlled trials, interrupted time series, and controlled before-after designs). MEDLINE, EMBASE, Cochrane Library, CINAHL, and relevant reference lists were searched until March 2013. Two reviewers independently assessed studies for inclusion, quality, and extracted data. Eleven studies, assessing the impact of seven policy changes, were included: 2 separate reports of one randomized controlled trial, 4 interrupted time series, and 5 controlled before-after studies.

Findings: Outcomes included medication adherence, clinical events (myocardial infarction, stroke, death), quality of life, healthcare utilization, or cost. The heterogeneity among the studies precluded meta-analysis. Few studies reported the impact of cost sharing strategies on mortality, clinical and economic outcomes. The association between patient copayments and medication adherence varied across studies, ranging from no difference to significantly lower adherence, depending on the amount of the copayment.

Conclusion: Lowering cost sharing in patients with chronic diseases may improve adherence, but the impact on clinical and economic outcomes is uncertain.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Flow diagram depicting included and…
Figure 1. Flow diagram depicting included and excluded studies for the qualitative systematic review.
Figure 2. Overview of included studies.
Figure 2. Overview of included studies.
Figure 3. The association between cost sharing…
Figure 3. The association between cost sharing and medication utilization and adherence.
Figure 4. The association between cost sharing…
Figure 4. The association between cost sharing and drug and non-drug expenditures.
Figure 5. The association between cost sharing…
Figure 5. The association between cost sharing and clinically relevant outcomes.

References

    1. American Diabetes Association (2013) Standards of medical care in daibetes - 2013. Diabetes Care 36: S11–S66.
    1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, et al. (2004) JNC 7 Express: the seventh report for the Joint Committee on prevention, detection, evaluation, and treatment of high blood pressure. In: Servics UDoHaH, editor: National Institutes of Health; National Heart, Lungh, and Blood Institute. pp. 1–66.
    1. Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, et al. (2012) 2012 ACCF/AHA/ACP/AATS/PCNA/SCA/STS guideline for the diagnosis and management of patietns with stable ischemic heart disease. JACC 60: e44–e164.
    1. Grundy SM, Becker D, Clark LT, Cooper RS, Denke MA, et al. (2002) Third report of the National Cholesterol Education Program (NCEP) Expert Panel on the detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel III): final report. In: National Heart L, and Blood Institute editor: National Institute of Health. pp. 1–264.
    1. Levin A, Hemmelgarn B, Culleton B, Tobe S, McFarlane P, et al. (2008) Guidelines for the management of chronic kidney disease. CMAJ 179: 1154–1162.
    1. Hoffman JM, Li E, Doloresco F, Matusiak L, Hunkler RJ, et al. (2012) Projecting future drug expenditures - 2012. Am J Health-Sys Pharm 69: e5–e21.
    1. Haas JS, Phillips KA, Gerstenberger EP, Seger AC (2005) Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997–2000. Ann Intern Med 2005: 891–897.
    1. Goldman DP, Joyce GF, Zheng Y (2007) Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA 298: 61–69.
    1. Goldman DP, Joyce GF, Escarce JJ, Pace JE, Solomon MD, et al. (2004) Pharmacy benefits and the use of drugs by the chronically ill. JAMA 291: 2344–2350.
    1. Clark AM, DesMeules M, Luo W, Duncan AS, Wielgosz A (2009) Socioeconomic status and cardiovascular disease: risk and implications for care. Nat Rev Card 6: 712–722.
    1. Rabi DM, Edwards AL, Southern DA, Svenson LW, Sargious PM, et al. (2006) Association of socio-economic status with diabetes prevalence and utilization of diabetes care services. BMC Health Serv Res 6: 124 doi:
    1. Grotto I, Huerta M, Sharabi Y (2008) Hypertension and socioeconomic status. Curr Opin Cardiol 23: 335–339.
    1. Manns BJ, Tonelli M, Zhang J, Campbell DJT, Sargious P, et al. (2012) Enrolment in primary care networks: impact on outcomes and processes of care for patients with diabetes. CMAJ 184 doi:
    1. Austvoll-Dahlgren A, Aaserud M, Vist GE, Ramsay C, Oxman AD, et al. (2008) Pharmaceutical policies: effects of cap and co-payment on rational drug use. Coch Dat Sys Rev Art. No.:CD007017.DOI:.
    1. Gibson TB, Ozminkowski RJ, Goetzel RZ (2005) The effects of prescripton drug cost sharing: a review of the evidence. Am J Manag Care 11: 730–740.
    1. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288: 2981–2997.
    1. UKPDS Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352: 854–865.
    1. Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, et al. (2008) Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. NEJM 359: 2417–2428.
    1. CTT Collaborators (2012) Mihaylova B, Emberson J, Blackwell L, Keech A, et al. (2012) The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: a meta-analysis of individual data from 27 randomised trials. Lancet 380: 581–590.
    1. EPOC (2012) EPOC Methods. In: Group CEPaOoC, editor. Ottawa: Cochrane Collaboration.
    1. Higgins JPT, Altman DG, Gotzsche PC, Juni P, Moher D, et al. (2011) The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 343: d5928.
    1. Brook RH, Ware JE Jr, Rogers WH, Keeler EB, Davies AR, et al. (1983) Does free care improve adults' health? NEJM 309: 1426–1434.
    1. Keeler EB, Brook RH, Goldberg GA, Kamberg CJ, Newhouse JP (1985) How free care reduced hypertension in the health insurance experiment. NEJM 254: 1926–1931.
    1. Pilote L, Beck C, Richard H, Eisenberg MJ (2002) The effects of cost-sharing on essential drug prescriptions, utilization of medical care and outcomes after acute myocardial infarction in elderly patients. CMAJ 167: 246–252.
    1. Schneeweiss S, Patrick AR, Maclure M, Dormuth CR, Glynn RJ (2007) Adherence to beta-blocker therapy under drug cost sharing in patients with and without acute myocardial infarction. Am J Manag Care 13: 445–452.
    1. Schneeweiss S, Patrick AR, Maclure M, Dormuth CR, Glynn RJ (2007) Adherence to statin therapy under drug cost sharing in patients with and without acute myocardial infarction: a population-based natural experiment. Circulation 115: 2128–2135.
    1. Zhang Y, Donohue JM, Lave JR, O'Donnell G, Newhouse JP (2009) The effect of Medicare Part D on drug and medical spending. NEJM 361: 52–61.
    1. Liu S-Z, Romeis JC (2004) Changes in drug utilization following the outpatient prescription drug cost-sharing program - evidence from Taiwan's elderly. Health Policy 68: 277–287.
    1. Doshi JA, Zhu J, Lee BY, Kimmel SE, Volpp KG (2009) Impact of a prescription copayment increase on lipid-lowering medication adherence in veterans. Circulation 119: 390–397.
    1. Zhang Y, Lave JR, Donohue JM, Fischer MA, Chernew ME, et al. (2010) The impact of Medicare Part D on medication adherence among older adults enrolled in Medicare-Advantage products. Med Care 48: 409–417.
    1. Zhang Y, Donohue JM, Lave JR, Gellad WF (2011) The impact of Medicare Part D on medication treatment of hypertension. Health Research and Educational Trust 46: 185–198.
    1. Li P, McElligott S, Bergquist H, Schwartz JS, Doshi JA (2012) Effect of Medicare Part D coverage gap on medication use among patients with hypertension and hyperlipidemia. Ann Intern Med 156: 776–784.
    1. Fineberg HV (2012) A successful and sustainable health system - how to get there from here. NEJM 366: 1020–1027.
    1. Keehan SP, Cuckler GA, Sisko AM, Madison AJ, Smith SD, et al. (2012) National health expenditure projections: modest annual growth until coverage expands and economic growth accelerates. Health Aff 31: 1600–1612.
    1. Reeder CE, Lingle EW, Schulz RM, Mauch RPJ, Nightengale BS, et al. (1993) Economic impact of cost-containment strategies in third party programmes in the US (part 1). Pharmacoeconomics 4: 92–103.
    1. Smith DG, Kirking DM (1992) Impact of consumer fees on drug utilisation. Pharmacoeconomics 2: 335–342.
    1. Piette JD, Heisler M, Wagner TH (2004) Cost-related medication underuse among chronically ill adults: the treatments people forgo, how often, and who is at risk. Am J Pub Health 94: 1782–1787.
    1. Huttin C (1994) The use of prescription charges. Health Policy 41: 53–73.
    1. Freeman JD, Kadiyala S, Bell J, Martin D (2008) The causal effect of health insurance on utilization and outcomes in adults: a systematic review of US studies. Med Care 46: 1023–1032.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する